Share on LinkedInShare on LinkedIn

ARTICLE · 17 JULY 2026

Reexams Are An Alternative, Not A Fallback: Presentation, Without Consideration, Still Counts Under 35 U.S.C. § 325(d)

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Contributor
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Mintz is a litigation powerhouse and business accelerator serving leaders in life sciences, private...

View firm profile
Explore more from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

As we have previously addressed (here and here), the PTAB landscape has changed dramatically over the past year, particularly with respect to inter partes review (“IPR”) institution practices.

United StatesIntellectual Property

The Next Landscape Shift, and Why It Matters

As we have previously addressed (here and here), the PTAB landscape has changed dramatically over the past year, particularly with respect to inter partes review (“IPR”) institution practices. Understandably, patent challengers have pulled back from IPRs and looked for another vehicle outside of the Patent Trial and Appeal Board (“PTAB”) to carry their invalidity arguments. Ex parte reexamination (“Reexam”) proceedings—which have not, to date, been subject to PTAB’s discretionary denial/settled expectations framework that has helped flip the ratio of granted versus denied IPR institution decisions since 2025—appeared to be a good fit under the circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from